3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myeloid, Acute
17
Myelodysplastic Syndromes
9
Leukemia, Myelomonocytic, Chronic
4
Myeloproliferative Disorders
3
Myelodysplastic-Myeloproliferative Diseases
2
Leukemia, Biphenotypic, Acute
2
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Systemic Mastocytosis With an Associated Hematologic Neoplasm
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Hodgkin Disease
1
GATA2 Deficiency
1
Cytopenia
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
BRCA1 Mutation
1
Anemia, Refractory, with Excess of Blasts
1
Allogeneic Stem Cell Transplantation
1
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
pembrolizumab
5
cabozantinib
5
Everolimus
5
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
Etoposide
2
Cisplatin
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
telotristat ethyl
1
surufatinib
1
repotrectinib
1
peposertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
decitabine and cedazuridine drug combination
×
90 days
×
Clear all
No trials found.